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Abstract 
Modern adjuvants should induce strong and balanced immune responses and it is 
often desirable to induce specific types of immune responses. As an example 
efficient Th1-immunity inducing adjuvants are highly in demand. Such adjuvants 
promote good cellular mediated immunity against subunit vaccines having low 
immunogenicity themselves. The development of such adjuvants may take advantage 
of the increased knowledge of the molecular mechanisms and factors controlling 
these responses. However, the knowledge of such molecular details of immune 
mechanisms are relatively scarce in other species than human and laboratory 
rodents and, in addition, there are special considerations pertaining to the use 
of adjuvants in veterinary animals, such as production and companion animals. 
With a focus on veterinary animals, the review highlights a number of approaches 
being pursued, including cytokines, CpG oligonucleotides, microparticles and 
liposomes. 
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Introduction 
 
Vaccines are compositions containing non-pathogenic, and sometimes non-
infectious, variants of infectious or transmissible pathogenic agents. When 
administered to a host they induce short-term (within weeks) as well as long-
lasting (years, sometimes lifelong) specific immunity in the vaccinated host 
against the particular pathogen imitated by the vaccine. Immunity can be defined 
as preparedness and capacity to neutralize a given agent by appropriate, 
protective defence responses.  
 
Since the late 18th century discovery by Jenner that vaccinia (cowpox virus) 
could be used a reliable vaccine against the related smallpox virus (108) 
vaccine development has been largely empirical, using live attenuated or killed 
microorganisms and/or detoxified versions of their toxins (38, 71, 119, 121). 
Still, mass vaccination programmes have eradicated smallpox and dramatically 
reduced polio in humans and eradicated rinderpest in cattle (74, 116) and 
vaccination remains the most cost-effective way of controlling infectious 
diseases (71). Closely linked to vaccine development, vaccine potentiating 
compounds (adjuvants) have continuously been developed. They comprise a plethora 
of working mechanisms and a broad variety of molecules some of which have been 
used widely for many years (34, 128, 135).  
 
Although vaccines for use in livestock animals like cattle, pigs, sheep, goat, 
poultry and farmed fish as well as in companion animals like dogs, cats, and 
horses have the same general goal as those used for humans, there are a range of 
different demands to be met. Some of these are related to the use of the animal 
for human consumption or as companion animals, while others relate to how to 
design and use vaccines in the best way, considering animal production (rearing) 
practices, herd epidemiology and animal trade. With livestock animals there is 
also a considerable focus on direct (vaccine) and indirect (effect on growth 
rates) costs of vaccines which is not a primary concern for companion animals. 
Additional points are the challenges and opportunities offered by different 
species (e.g. fish and chickens) with respect to administration practices and 
routes, especially in order to vaccinate high numbers of animals in a short 
time.  
Thus the use of adjuvants and, especially, the rational development of new 
adjuvants and immunostimulators for veterinary animals demand special attention 
and it is appropriate to consider some recent examples of adjuvant research with 
a specific focus on their use in animals of veterinary significance. 
  
Background 
A number of recent reviews giving excellent updates on the immune system and the 
mechanisms of adjuvants have been published recently (1,48,125). For the sake of 
clarity and consistency a few central concepts will be restated here. 
 
The pivotal discrimination between threats (pathogens and their toxins) and non-
threats (self antigens, innocuous environmental antigens) is exerted by the 
physiological barriers of the body together with the innate part of the immune 
system (29,120). The central innate cellular actors, the dendritic cells (DC) 
when activated secrete potent pleiotropic signal molecules activating the 
adaptive immune system to respond against any extraneous molecule involved. If 
the innate immune system is not activated adaptive immune responses are very 
rarely induced. A limited number of highly conserved molecular structures 
specific to microbial pathogens, the so-called pathogen-associated molecular 
patterns (PAMPs) are well-described innate immune triggers (57). When bound by 
pattern recognition receptors (PRRs) including the Toll-like receptors (TLR) on 
DCs very fast innate responses are induced (120). The TLR family was named after 
the toll protein originally found to be involved in Drosophila development (5) 
and later found to have structural homologies with the human IL-1 receptor 
Heegaard et al., Adjuvants and delivery systems in veterinary vaccinology 4 
implying immunological functions. This led to the identification of a growing 
family of vertebrate TLR, each associated with a particular ligand (agonist) 
type and cellular location (Table 1). 
 
While the distinction between threats and non-threats takes place in the innate 
immune system self – non-self discrimination takes place in the adaptive immune 
system after activation by the innate immune system. The adaptive immune system 
with its wide range of exquisitely fine-tuned antigen-specific responses, 
controlled by T- and B-cells in combination with antigen presenting cells (APCs) 
brings antigenic specificity to immune responses and provides memory (long-
lasting immunity). Memory is a central asset of immunity (20,71) and relies upon 
the generation of long-lived optimally reactive antigen-specific T and B cells 
and long-lived plasma cells producing high-affinity antibodies (20,71). A subset 
of effector T cells, after performing their tasks at the site of infection 
survives and differentiates into such long-lasting memory T cells responding 
rapidly to low doses of antigen (86, 125). Memory B cells rapidly express high 
affinity antibodies (125) upon antigenic restimulation. While the composition of 
the preferred immune response induced by a vaccine depends on the type of 
infectious agent targeted by the vaccine, a vaccine should always induce 
immunological memory. 
 
The innate immune system also controls the type of adaptive response. This is 
mediated by soluble molecules secreted by activated DC (120,125,140)(see Figure 
1, Suppl. info.). Some pathogens will activate DCs to produce cytokines 
(including interleukin (IL) -12) stimulating development of T helper cells that 
produce interferon- (IFN-) γ and promote cell-mediated immunity (Th1 cells). 
Other types of stimuli (160) induce Th2 cells producing IL-4, IL-5 and IL-13 
promoting antibody-based immunity efficient at neutralizing extracellular 
pathogens and toxins (86, 125)(see Figure 1, Suppl. info.). Also, generation of 
immunological memory is intimately dependent on innate immune reactions 
accompanying the initial encounter between host and vaccine (125). 
 
Adjuvants primarily affect the innate, immunity-shaping pre-primary immune 
response and innate immunity has been called “The Science of Adjuvants” (125). 
Adjuvants must enhance both specific immune responses as well as increase 
immunological memory and improve protection through stimulation of optimal types 
of immunity. Adjuvants are also required to have low levels of adverse effects, 
including for veterinary animals adverse effects that negatively influences the 
growth of the animal, the reproduction rate, the comfort and welfare of the 
animal or cause carcass blemish. Adjuvants must also be stable and easy to use 
providing convenient injectability.  
 
Traditional adjuvants are mostly complex and not very well-defined mixtures of 
surface-active compounds, microbial components and/or various polymers and 
lipids and can be classified into delivery systems/antigen modifiers or immune 
potentiators, or combinations of these (see Table 2)(42, 94). Delivery 
systems/antigen modifiers function by presenting, aggregating and/or 
polymerising antigens (42, 48, 161). Immunopotentiators include PAMP structures, 
endogenous immunoactive compounds, (cytokines a.o.) and a range of surface 
active molecules directly stimulating innate immune cells. Examples of PAMP 
structures used as immunopotentiators are monophosphoryl lipid A and 
unmethylated CpG oligonucleotides (42, 48). Next to alum (aluminium salts), 
which is still the only adjuvant class generally approved for human use, 
emulsions of water-in-oil or vice versa stabilised by surfactants, are the most 
widely used adjuvant systems and include Freund’s adjuvant. Other well-known 
delivery systems include liposomes and microparticles, which are inert carriers 
of antigen unless immune potentiators have been added to them (48, 119).  
 
Heegaard et al., Adjuvants and delivery systems in veterinary vaccinology 5 
Modern vaccines based on sub-units of pathogens, e.g. purified proteins are 
often unable to evoke strong immune responses. Therefore adjuvants, in 
particular safe and efficient Th1 inducing adjuvants are in increasing demand 
(134). Freund’s complete adjuvant (1, 48) is an efficient Th1 inducer however 
has a high and generally unacceptable level of adverse local effects. 
 
Adjuvant safety: Efficiently inducing immunity without causing 
harm. 
Adverse effects and potential hazards 
Mild local and systemic reactions to vaccines and their adjuvants are to be 
expected as a natural consequence of vigorously stimulating the immune system 
(129, 137). These adverse effects are influenced by the interactions of the 
specific adjuvant and antigen and the type of adverse reaction will vary 
according to the vaccine used. For example, temperature rise with associated 
reduction or cessation of feeding, dullness and reduced milk production (if 
lactating) is frequently associated with live vaccines. Bacterial crude extracts 
often induce strong local reactions when administered in emulsion, as they may 
contain strongly immunostimulating compounds like lipopolysaccharide or 
peptidoglycan fragments, responsible for the induction of secondary reactions. 
 
Many vaccine side effects are trivial and of short duration and are usually 
associated with live vaccines. Sometimes adjuvants in a vaccine can cause an 
adverse reaction, sometimes latent infections can be reactivated, and sometimes 
an animal may fail to respond (107). Other well-known side effects include: 
transient swelling at the site of injection and a reaction that may change coat 
colour in the area; transient fever; respiratory distress, salivation, vomiting, 
diarrhoea, urticaria; arthritis, uveitis, anorexia, soreness, lethargy; reduced 
fertility, foetal deformities and abortion. Considering the many millions of 
doses of vaccine sold annually and used in farm animals, such adverse side 
effects are very rare (131) when vaccines are used as intended by the 
manufacturers, and safety testing of vaccines helps prevent their occurrence. 
With killed vaccines the most common side effects are local, presenting 
themselves around the injection site, especially if using an adjuvant that 
delays antigen release. However, such reactions can also occur in vaccines not 
containing an adjuvant and therefore it is usually advised that the vaccine, 
particularly if injected subcutaneously, should be introduced into an area of 
the animal not used for human consumption such as behind the animal’s ear or in 
the area of the chest wall behind the elbow. Then if there is any residual 
vaccine left or any reaction to it, there will be neither involvement of an 
edible part of the carcass nor trim losses in food animals (131). 
 
Injection site reactions 
Injection site reactions are of great concern in food-producing animals as 
reviewed by Roth (129) and Spickler and Roth (137) in cattle, swine, sheep and 
chicken. They may lead to unacceptable blemishes in, or decreased quality of, 
meat intended for human consumption. There are many possible causes of injection 
site lesions, including organisms introduced with a contaminated needle, live 
contaminating organisms in the vaccine, adjuvant induced reactions, cytokine 
release, hypersensitivity reactions (type I, II, III, or IV), trauma, and 
haemorrhage. Injections of vaccines into the subcutis can result in the 
development of palpable granulomatous nodules due to adjuvants and other highly 
immunostimulatiory vaccine components inciting persistent local immunologic 
responses (50). Histologic changes consist of a localized area of deep dermal or 
subcutaneous necrosis containing foreign material thought to be adjuvant or 
vaccine components. The central zone of foreign and necrotic material is 
bordered by macrophages and multinucleated giant cells with a peripheral zone of 
lymphocytes and variable numbers of plasma cells and eosinophils (foreign body 
granuloma)(Figure 2, Suppl. info.). Macrophages usually contain amphiphilic 
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granular foreign material. Lymphoid follicular development at the margins of 
these lesions can be extensive. Vaccine-associated granulomatous inflammation 
has also been reported in the peritoneum (123) and muscle (79) of fishes, with 
consequent retarded growth and downgrading during processing.  
 
Vaccine-induced neoplastic disease  
Although injection site lesions often heal without serious consequences, in cats 
there is a causal relationship between postvaccination inflammation and 
development of fibrosarcomas, osteosarcomas, rhabdomyosarcomas, malignant 
fibrous histiocytomas, and chondrosarcomas (53). Antigen load and degree of 
persistent inflammation and eventual fibroblastic proliferation caused by 
subcutaneous vaccine administration are thought to be important factors 
predisposing to tumour development in cats. It is speculated that during tissue 
repair, fibroblasts or myofibroblasts are stimulated by the immunogenic 
substances in the vaccine reaction site and this, in combination with other 
factors such as oncogene alterations or unidentified carcinogens, leads to 
malignant transformation of cells. Tumour development can take months to years, 
with eventual neoplastic transformation of mesenchymal cells. 
 
The incidence of such fibrosarcomas occurring at sites commonly used for 
vaccination in cats has increased in recent years (53), and although still 
regarded as rare (estimates of approx 1 to 2 cases/10,000 vaccinated cats), 
vaccine-associated fibrosarcomas are arguably the most serious vaccine adverse 
events reported in cats (Figure 3. Suppl. info.). More recently a similar 
pathological entity has been reported also in ferrets (109) and dogs (153). 
Histologically, feline postinjection fibrosarcomas are characterized by 
inflammatory peritumoural infiltration, multinucleated giant cells, and 
myofibroblastic cells.  
 
Vaccine-associated sarcomas were recognized in 1991 following the introduction 
of an aluminium adjuvanted FeLV vaccine and the transition from modified-live 
rabies virus vaccines to adjuvanted killed rabies virus vaccines in the mid 
1980s. Epidemiological evidence of a causal association between vaccination with 
aluminium salt adjuvanted rabies virus and FeLV vaccines has also been 
established (70) and vaccine adjuvant-induced inflammation at the injection site 
has been implicated as the cause (61). However, results of a multicenter case-
control study (70) of risk factors did not support the hypothesis that the risk 
of sarcoma formation was associated with specific brands or types of vaccines. A 
direct association between the presence or severity of postvaccinal inflammation 
and tumour risk has not specifically been established, but after taking all 
currently available evidence into consideration, the 2006 American Association 
of Feline Practitioners Feline Vaccine Advisory Panel Report suggested that 
veterinarians use less inflammatory products whenever possible (127). Adjuvanted 
rabies vaccines appear to induce greater inflammation than do nonadjuvanted 
rabies vaccines, and the same appears true for FeLV vaccines. Administering 
injectable vaccines in specific recommended sites on the body facilitates 
monitoring vaccine site reactions and managing sarcomas, should they develop 
(127). 
 
Safety of oil-based adjuvants  
Oil-based adjuvants are among the most efficient adjuvants known and they are in 
wide use for veterinary vaccines, however they may induce local and general 
reactions, like granuloma, abscesses or fever (8). The mineral oils in use for 
these purposes are a mix of several hydrocarbon chains of different lengths. 
Small chains are efficient but induce local reactions, whereas longer chains (> 
C14) are safer but less efficient. Medium-length chains are preferred (C16-C20). 
The solubilising and detergent properties of small chains are probably 
responsible for these local reactions. Highly purified non mineral oils are well 
tolerated as they are rapidly metabolised and eliminated from the injection 
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site, inducing a weak and transient local inflammatory reaction only. In 
contrast, mineral oils tend to reside at the injection site and are 
progressively eliminated by competent cells like macrophages as well as being 
partially metabolised to fatty acids, triglycerides, phospholipids or sterols. 
Bollinger et al. (15) demonstrated that in rats and squirrel monkeys 30% of the 
mineral oil disappears during the first month and the majority of the oil found 
outside the injection site is in the liver and fat tissues in the form of 
phospholipids and fatty acids.  
 
Generally, water-in-oil emulsions (W/O) are recommended for bovine, small 
ruminants, poultry and fish when long term immunity is required. In the case of 
foot and mouth disease, mineral oil based emulsions can protect bovines for one 
year with one vaccination whereas formulations based on aluminium hydroxide 
required two boosts or more. Even if some local reactions occur, W/O emulsions 
can be used when the protection against specific diseases as compared to other 
formulations or other routes of administration, is enough to justify some side 
effects. This is the case for fish vaccines against furunculosis, where the 
procedures can be limited to one injection as the protection is maintained 
during the whole growing period. W/O emulsions also allow reduction of the 
vaccine dose or the antigen concentration. W/O formulations can also enhance 
cellular immune responses. Vaccination of sheep against heartwater with W/O 
formulations enhances protection against challenge and are well tolerated. 
Miglyol 840-based (medium-chained triglyceride) vaccines containing Newcastle 
Disease and Infectious Bronchitis (IB) virus showed no local reactions at all, 
nor any vaccine residues, except for the W/O type of emulsion, which showed some 
traces of the inoculum. In contrast, equivalent vaccines containing mineral oil 
showed moderate local reactions at the injection site 12 weeks after inoculation 
when monitored by post-mortem macroscopic inspection (59). Similarly, Fukanoki 
et al. (43) detected cyst formation, granulomatous reaction and abscesses at the 
injection site 8-16 weeks after administration of oil adjuvanted vaccines 
prepared with various liquid paraffins in chickens. The vaccine with liquid 
paraffin mainly consisted of n-C16H34~n-C20H42 and induced less severe problems 
due to adverse local reactions such as inflammatory responses and persistent 
residual oil.  
 
Water-in-oil-in water emulsions (W/O/W) are of interest for their low viscosity 
and their ability to enhance both short and long term immune response. In foot 
and mouth disease, such formulations are able to protect swine as well as 
bovines against the disease only four days after vaccination which can be very 
useful in case of outbreak. However, multiphasic emulsions can also induce long 
term immunity and protect bovines against haemorrhagic septicaemia for one year 
after only one vaccination. Those based on mineral oil are recommended for 
swine, however, with reactive antigens it is preferable to avoid vaccination of 
fattening pigs as carcass blemish can be caused. Oil-in-water emulsions (O/W) 
are very fluid, well tolerated and induce strong short term immune responses. 
The oil phase ratio is very low, between 15 and 25%, which partly explains their 
safety. Emulsions based on mineral oil can be safely used for fattening pigs in 
order to enhance antibody responses against bacterial or viral infection but 
also the potency of live vaccine like pseudorabies vaccine.  
Vaccines for pets and horses must not induce any local reactions and then O/W 
emulsions based on non mineral oil are adapted. Water dispersed liquid 
nanoparticles (10 to 500 nm) combined with an immunostimulating compound is an 
interesting new adjuvant concept (socalled “immunosol” adjuvants)(8). Trials in 
swine against atrophic rhinitis or pleuropneumonia demonstrated that such 
formulation could enhance immune response without inducing local reactions 
(87,88) and vaccination of bovine against anaplasmosis gave 100% protection. 
Moreover fish trials confirmed their good efficacy and safety and various trials 
in pets and horses are ongoing (8).  
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- Conclusions and perspectives 
There is no universal adjuvant and there is always a trade-off between safety 
and efficacy (8). Also, the adjuvant must be adapted to the target species, the 
antigens, the desired type of immune response, the route of inoculation, and the 
desired duration of immunity.  
Water in oil (W/O) emulsions induce strong, long term immunity, however can 
sometimes induce local reactions with reactive antigens. Non mineral oils are 
well tolerated but less efficient with poor immunogens. Multiphasic (W/O/W) 
emulsions can induce short and long term immune responses and oil in water (O/W) 
emulsions are well tolerated and induce a short term immune response. Bovine and 
chickens can be vaccinated with W/O emulsions whereas swine generally require 
well tolerated adjuvant like O/W emulsions. Also, the antigen type will 
influence the selection. Mineral oils can be used when non reactive antigens 
like purified proteins or synthetic peptides are used. Non mineral oils are 
preferable with more reactive antigens. W/O/W and O/W can be used with live or 
DNA vaccines. Adjuvants must be able to enhance humoral or cellular mediated 
immunity according to the mechanism of protection against the disease. W/O 
emulsions are able to induce cellular response. W/O/W or O/W enhance humoral 
responses but have also been associated with enhancement of cellular responses. 
The duration of immunity has also to be considered and the selection of the 
adjuvant is different if short or long term immunity is required. The route of 
inoculation is also important, e.g. subcutaneous and intramuscular 
administration of the same vaccine formulation can give different immune 
responses. New generations of oils and surfactants may allow the development of 
stable safe and fluid emulsions (8, 26).  
Molecularly defined adjuvants: Toll-Like Receptors and the use of 
PAMP agonists as adjuvants in farm animals. 
As described above the innate immune response to pathogens provides a rapid 
early reaction to host invasion. This response initiates a range of inflammatory 
reactions through the expression of signalling proteins by infected and antigen-
presenting cells.  Proteins such as interferons, cytokines and chemokines 
mediate this activation as well as the chemo-attraction of a number of cell 
types including macrophages, lymphocytes, polymorphonuclear leukocytes and mast 
cells.  This in turn paves the way for the development of the adaptive immune 
response and influences the development of antibody and cell-mediated responses.   
Whilst the innate immune response has evolved to enhance the survival of animals 
in the face of microbial invasion, it can itself result in damage to cells and 
structures within the host.  Indeed, chemokines have been associated with 
autoimmune and cardiovascular disease in domestic animals (reviewed by Gangur et 
al.(44)), and many viruses encode genes that mimic chemokines or their receptors 
(111). Unsurprisingly the control of the innate immune system occurs early in 
the recognition process and is provided by groups of receptor proteins both at 
the cell surface and intracellularly that detect pathogens through engagement 
with integral pathogen structures known as pathogen-associated molecular 
patterns (PAMP). Examples of PAMPs are cell wall components for bacteria or 
particular nucleic acid structures unique to viruses such as double-stranded RNA 
(33,96,141).   
A key component of this pathogen detection system is the toll-like receptor 
(TLR) family whose members have been identified throughout the animal kingdom.  
A principal benefit for the evolution of this system is economy. A relatively 
small number of TLR, and other receptors including NOD-like and RIG-I receptors 
(reviewed by Creagh and O’Neill (24)) are able to detect a large range of 
pathogens at locations where pathogen-cell interactions can take place i.e. the 
cell surface, within endosomes and within the cell cytoplasm. The identification 
of such receptors and their agonists provides an opportunity to develop vaccine 
strategies that both enhance and focus the immune response in ways that are 
Heegaard et al., Adjuvants and delivery systems in veterinary vaccinology 9 
beneficial to the animal. In contrast to the TLR family, homologues for NOD-like 
and RIG-I-like receptors have not been identified in large farm animals. 
A key feature of the TLRs is their conserved structure. Each mature TLR can be 
divided into three functional domains (12); an ectodomain that is dominated by a 
continuous series of leucine-rich repeats (LRR) that forms the pattern-
recognition structure; a transmembrane domain that anchors the glycoprotein in 
the cell membranes and a Toll IL-receptor (TIR) domain that forms the 
cytoplasmic signalling domain. Specific PAMP recognition is through the LRRs of 
which there are between 16 and 28 within the ectodomain.  Individual LRRs 
typically have a structure of LxxLxLxxNxL in which “L” is Leu, Ile, Val or Phe 
and “N” is Asn, Thr, Ser or Cys (extensively reviewed in Matsushima et al.(101). 
TLR3 provides a useful example of the features of this family of receptors.  It 
is associated with endosomal membranes with the ectomain directed to the lumen 
of the endosome itself. TLR3 binds double-stranded RNA (3) and is a key receptor 
for the detection of RNA viruses (100, 102).  The crystal structure of human 
TLR3 ectodomain has been solved at 2.1 angstroms and reveals a horseshoe-shaped 
molecule.  The structure is heavily glycosylated with a single glycosylation-
free surface that could bind ligands, and the conserved segments provide a 
likely site for homodimer formation (23). Complete TLR3 coding sequences have 
been identified in a range of large veterinary animals including cattle 
(NM_001008664; 21), pig (DQ647698) and horse (DQ266434). A partial sequence for 
sheep has also been obtained (AY957614; 104). Alignment of human and bovine TLR3 
(Figure 4, Suppl. info.) demonstrates the high degree of sequence homology 
suggesting a conservation of function among higher mammals. This also implies 
that TLR agonists (discussed below) that have been developed in small animal 
models should engage TLRs in larger animals although this must be tested 
empirically for both toxicity and efficacy. Certainly bovine macrophages and 
dendritic cells produce nitric oxide (NO) and cytokines in response to some 
common TLR agonists including lipopolysaccharide, poly (I:C) RNA and CgG-DNA 
(157).  
Concerning TLRs in farm animals, there is growing evidence that they are 
actively engaged in response to infection (158). In cattle, specific increases 
in TLR2 have been observed during mastitis infection (46) and porcine 
macrophages up-regulate TLR2 and 6 in response to infection with Mycoplasma 
hyopneumoniae (110), a major contributor to endemic pneumonia within swine. Many 
innate response genes, including TLR3, are activated in newborn calves following 
bovine rotavirus infection (2). However, there is further evidence of pathogen 
subversion of this system. TLR2 detects peptidoglycan (Table 1), a major 
component of bacterial cell walls including Mycobacterium spp. However, 
Mycobacterium bovis may use this to enhance uptake into phagocytes. Bovine viral 
diarrhoea virus (BVDV) infection has been shown to modulate TLR expression in 
bovine macrophages (41) and in bovine peripheral blood monocytes (90), 
influencing the production of NO, TNFa production and type 1 interferon gene 
expression.  
Can the TLR system be used to enhance veterinary vaccines?  Engagement of TLRs 
activates at least two signalling pathways (11) that lead to the induction of 
antimicrobial genes and inflammatory cytokines (58). Among these are the type 1 
interferons, tumour necrosis factor-alpha and interleukin-6. This suggests that 
inclusion of a TLR agonist within a vaccine preparation will induce a local 
inflammatory reaction and therefore fulfil the primary role of an adjuvant. TLR 
agonists also have the capacity to influence the development of the adaptive 
immune response, probably through recruitment and engagement of dendritic cells 
(58,159). Currently such agonists are being used as topical antiviral agents in 
humans (7,14) and are being included into vaccine vehicles for in vivo use 
(163). Indeed, one company (invivoGen) is offering a mouse TLR Agonist Kit 
containing an agonist for each class of TLR.  Despite a number of setbacks in 
the field of human vaccine development, approval has now been gained for the 
first alum based vaccine prepared in combination with a TLR agonist (MPL®, 
GlaxoSmithKline), named AS04 and developed for use with a hepatitis B vaccine.  
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The ability of TLR agonists to influence the adaptive immune system has obvious 
attractions for the development of vaccines against a number of infectious 
diseases of livestock and man.  Addition of such agonists would primarily be 
used to increase the magnitude of the immunological response, whether antibody 
or cell-mediated.  This might also enhance the development of immunological 
memory. Secondly, the formulation could sway the immune response towards a 
particular Th response and would be of specific interest to those developing 
animal vaccines against intracellular pathogens, e.g. bovine tuberculosis 
(Mycobacterium bovis) that need a Th1-like response to be counteracted 
efficiently. Thirdly, inclusion of a TLR agonist might reduce the response time 
between vaccination and protection. This would be particularly useful for 
reactive vaccination in response to outbreaks such as foot and mouth disease and 
bluetongue virus or where post-exposure prophylaxis is required i.e. rabies 
virus. Currently, most of what we know of the TLR system has been derived from 
the mouse model and their practical applications, unsurprisingly, are in the 
field of human medicine. However, the inclusion of TLR agonists in human 
vaccines heralds the way for use of such compounds in the veterinary field. 
 
 
Molecularly defined adjuvants: CpG oligonucleotides as PAMP 
adjuvants in pigs 
Certain short, synthetic unmethylated oligodeoxynucleotides (ODNs) containing 
CpG ((5’cytosine-guanine 3’) dinucleotide motifs show a strong immunostimulatory 
activity towards murine B cells (81) emulating the immune stimulatory activity 
of bacterial DNA preparations (144) (see reviews by Krieg (82) and Klinman et 
al. (78)). Unmethylated CpG motifs occur much more frequently in bacterial and 
protozoan DNA than in vertebrate DNA and therefore represent a class of PAMPs. 
The immunostimulatory activity depends on the intracellular CpG specific Toll-
like receptor 9 (TLR9)(47) with CpG being taken up by the cell by endocytosis 
(113). In humans B cells and plasmacytoid dendritic cells (pDCs) express TLR9 
and are primary targets for CpG ODNs. The responsiveness of immature 
plasmacytoid dendritic cells, also called natural interferon producing cells to 
CpG ODNs has been confirmed with pig cells (49).  
 
As originally shown by Krieg et al. (81) CpG ODNs have immediate (8 hours), 
highly sequence specific stimulatory effects on mouse spleen cell cytokine and 
IgM secretion. Methylation of cytosine as well as replacement of either C or G 
completely abolished activity. Also, two purine bases should flank the CpG motif 
at its 5’–end and two pyrimidine bases should be present at the 3’-end for 
optimal activity, i.e. PuPuCGPyPy. GACGTT was a preferred motif in mice (81) and 
multiple CpG motifs increased activity. These initial studies in mice have been 
followed up by studies in cattle, sheep, pigs, horses, dogs, cats and fish (see 
Mutwiri et al. (113). CpG motifs with optimal stimulatory activity differ 
between species, possibly reflecting differences towards the specific pathogens 
preferentially infecting these species. In cattle, Brown et al. (19) showed that 
Babesia bovis DNA stimulated bovine B cells to proliferate and to produce IgG, 
related to the presence of unmethylated CpG sequences in the DNA that could be 
mimicked by synthetic ODNs, one immunostimulating sequence being identified as 
AACGTT. In humans optimal sequences were ATCGAT (type D, phosphodiester, 
conforming to the PuPyCGPuPy rule) and GTCGTT (type K, phosphorothioate)(155))1. 
In pigs the palindromic type D sequence ATCGAT in a 20-mer ODN, having a 
phosphodiester core flanked by phosphorothioates at both ends was one of the 
most active motifs (65). The high activity of ODNs with phosphodiester cores and 
phosphorothioate 5’ and 3’ ends (chimeric ODNs) is a general finding with type D 
ODNs which are further enhanced by poly G stretches at both ends of the ODN 
                                                 
1 Type D and K ODNs (155) are also called type A and B, respectively (84). 
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(84). Type K is optimally active as all-phosphorothioate molecules often 
containing multiple CpG motifs and with no demand for poly G motifs (82). In 
contrast to what has been demonstrated in sheep (16) the cytokine response of 
pig lymph node derived cells was found to be lower than that of pig PBMC (27), 
possibly linked to a lower constitutive TLR9 expression and a lower frequency in 
pigs of IFN-alpha producing cells in lymph node cells compared to PBMCs. 
 
Immunostimulating CpG ODNs generally induce Th1-like responses characterized by 
IL-1, IFN-, TNF-, and IL-12 production and in some cases IFN- and IL-6, 
generating cytotoxic T cells (82,155). CpG ODNs can even shift an ongoing Th2 
response into a Th1 response (113). As Th1-type adjuvants CpG ODNs are 
potentially useful in vaccines against intracellular pathogens, including 
viruses. It is also of great interest that CpG can work through mucosal routes 
of administration boosting mucosal responses (95, 115).  
 
In vivo, a short half-life and adsorption by non-relevant tissue are limiting 
factors for the use of CpG ODNs. Natural backbone (phosphodiester) ODNs are 
degraded within minutes, however inclusion of phosphorothioate backbones 
increase plasma half-lives to up to 60 minutes and with tissue half-lives around 
48 hours, as shown by studies in mice (113). Relevant delivery may be enhanced 
with targeting/delivery vehicles, e.g. transfection reagents, and/or by 
increasing concentration in the relevant tissue by increasing dose and/or 
prolonging release. Furthermore, as with DNA vaccines (152), the efficiency of 
CpG ODNs depends on efficient translocation of DNA into cells. This can be 
achieved in a number of ways using traditional adjuvants, with liposomes and 
polymer-based particles also potentially useful. In a recent study in cattle 
(80) combinations of CpG ODN, indolicidin and polyphosphazene were tested for 
ability to increase immunogenicity of hen egg white lysozyme and results 
indicated a humoral and cellular immunity enhancement both by complex formation 
between adjuvant and antigen and by the ability of polyphosphazene to increase 
the cytokine inducing abilities of CpG ODN and indolicidine. Humoral and 
cellular immunity was increased to the same level as by the oil-in-water 
adjuvant Emulsigen®. It is generally found that antigen specific immunogenicity 
may be augmented by binding the CpG ODN to the antigen or maintaining close 
contact between antigen and CpG ODN in other ways (78). 
 
Inter-individual variability in responses to CpG ODN has been a frequent finding 
in outbred populations which may indicate that CpG sensitivity is partly 
genetically controlled (49, 65, 103, 113, 156).  
  
CpG ODN, - as the only adjuvant sofar- was found to significantly increase both 
cell mediated immunity and humoral responses against PRRSV in pigs, and also 
protective efficacy in challenge models as reviewed by Charerntantanakul et al. 
(22, 95). Subcutaneous injection of a K-type ODN with multiple phosphorothioate 
CpG motifs resulted in dose-dependent significant increases in PRRSV–specific 
antibody titres, MHC-II expression by PBMCs, IFN-gamma secretion upon antigen-
specific stimulation of PBMCs in culture and in protection against disease and 
death (95). The “reverse” GpC analogue was much less active.  
Our own data (Sorensen et al. unpublished and Figure 4, Suppl. info.) show that 
type D CpG but not its “reverse” control ODN (GpC) are able to induce several 
cytokines in pig PBMCs while a more type K-like ODN is active both in its CpG 
and its GpC form and with increased induction of IL-6. van der Stede et al. 
(151) also found the activity of a CpG and its GpC analogue to be similar upon 
immunization of pigs with ovalbumin using a high intramuscular dose of 500 g 
ODN.
CpG ODNs were also found to increase protection against experimental infection 
in pigs with the parasite Toxoplasma gondii when injected in combination with 
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tachyzoites (83). CpG ODNs provided better protection and led to higher serum 
anti-parasite antibody levels in comparison with Freund’s incomplete adjuvant. 
The highly active ATCGAT palindrome defined by Kamstrup et al. (65) was found to 
increase the efficiency of a DNA vaccine against Pseudorabies virus infection in 
pigs, increasing protection, and humoral as well as cell-mediated immunity (30). 
The same vaccine was investigated by the oral route (95) where ODNs were found 
to increase systemic and mucosal antigen-specific antibody responses. Mixed 
phosphorothioate/phosphodiester backbones induced stronger IFN-gamma and 
proliferative responses than phosphorothioate-only ODNs while antibody responses 
were similar. In another study cell-mediated, Th1-type cytotoxic immunity 
against Hepatitis C virus was achieved by immunization with a plasmid coding for 
the NS3 protein of Hepatitis C, followed by boosting with recombinant NS3 mixed 
with CpG and Quil A (both in mice and pigs)(162). 
As shown by Kekarainen et al. (73) CpG motifs in viral genomes (in this case 
porcine circovirus type 2, PCV2) can also modulate host immune responses in a 
context dependent way; for example, CpG motifs originating from the PCV2 Rep 
gene were superior in inhibiting IFN-alpha production induced in recall 
responses with pseudorabies virus compared to other viral CpG motifs.  
 
Quite another use of CpG-based immunostimulators is for immediate, and 
transient, protection against infection, which was demonstrated for a range of 
bacteria, viruses and protozoa (reviewed by Klinman et al. (77) and Mutwiri et 
al. (113). Irrespectively of inoculation route, CpG ODNs protected mice against 
lethal doses of the intracellular bacteria Listeria monocytogenes and 
Francisella tularensis, provided the ODNs were administered prior to infection 
(optimally 3-14 days before, and weaning off at 21 days before). If ODNs were 
repeatedly injected, administration of the specific pathogen within the 
protected time frame led to the creation of prolonged pathogen-specific immunity 
(77). For “slow” pathogens as e.g. Leishmania monocytogenes protection could be 
achieved post-infection (77). The effect of mucosal delivery (intrapulmonary) of 
CpG ODNs was studied in sheep and it was found that a transient (lasting 2-5 
days) systemic acute phase and antiviral response took place, the effect of the 
ODN being highly increased by including an oil-in-water adjuvant (Emulsigen®) 
(115). These effects were also seen upon sc as well as intratracheal 
administration. In rainbow trout immunized with a combination of different 
salmonid rhabdovirus DNA protection against infection lasted for 4 days after 
vaccination and was apparently related to type I interferon induction (35). 
However, these effects are apparently not due to CpG as the involvement of TLR9 
could not be demonstrated (118), - instead the effect could be caused by the 
expressed rhabdovirus glycoproteins (76). 
 
Such CpG ODN mediated immediate innate responses do not rely on specific 
immunity, and are not antigen dependent. The protection is short-lived (days), 
unspecific and has no memory component. This has relevance for peri-exposure 
prophylaxis of herds of production animals e.g. against Foot-and-Mouth disease 
outbreak in neighbouring herds as was investigated in mice in which protection 
against challenge with 5 out of 6 different serotypes of foot-and-mouth disease 
virus (FMDV) was achieved (66). The protection lasted for 14 days. and, rather 
surprisingly, was also seen when ODN was administered simultaneously with or up 
to 12 hours after inoculation of the virus. Post-virus administration however 
had little effect on viraemia. For practical use as a means of FMDV control both 
protection against disease and inhibition of virus secretion are pivotal. This 
protection strategy does not interfere with monitoring through analysis of 
antibodies in blood samples (serodiagnosis). However, more recent data indicate 
that CpG has no effect on innate mediated early protection against FMDV promoted 
disease in pigs (4), in contrast to the findings in mice. CpG ODN mixed with 
Emulsigen ® and injected intramuscularly, did induce INF- for at least 4 days 
after injection, however did not protect pigs against disease at FMDV challenge 
2 days after a combined FMDV vaccine and CpG injection. Furthermore, with this 
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specific vaccine, CpG did not increase the protective effect of the vaccine as 
seen when challenge was performed more than 7 days after vaccination. This 
underlines the difficulties in interpreting effects of this type of adjuvants 
between species. 
 
As small, stable, and easily synthesizable molecules CpG ODNs hold promise as 
molecular adjuvants. Their strongly Th1-biased immunostimulatory activity, 
without the adverse effects frequently seen with traditional Th1 inducing 
adjuvants (mineral oil adjuvants, see above) complements the Th2-skewed activity 
of generally approved aluminium salt based adjuvants. They have potential for 
stimulation of mucosal immunity and show immediate activity against 
intracellular infections. The challenge is to define CpG ODNs with optimal 
activity in the species of interest, and being broadly active between individual 
animals. More knowledge is needed to define the optimal combination of antigens 
and ODNs, to establish practical administration routes as well as to elucidate 
long term adverse effects related to the possible generation of anti-DNA 
autoimmunity. 
 
Molecularly defined adjuvants: Endogenous mediators for targeting 
lymphocytes to mucosal surfaces. 
Retinoic acid 
Efficient induction of mucosal immunity most often employs vaccination at 
mucosal sites as parenteral immunization generally is ineffective at generating 
mucosal immune responses. This relates to the compartmentalization of mucosal 
and systemic immune responses, which is mainly based on the selective expression 
of homing receptors on lymphocytes. These receptors target effector and memory 
cells to specific ligands expressed in the extralymphoid site of the original 
antigen encounter (106). Thus, lymphocytes primed in the gut associated immune 
system, such as Peyer’s patches or mesenteric lymph nodes express the integrin 
α4β7 and the chemokine receptor CCR9 and subsequently migrate to the small 
intestinal mucosal tissues where their ligands, mucosal addressin cell adhesion 
molecule-1 and CCL25, respectively, are expressed by postcapillary venules and 
intestinal epithelial cells, respectively. In contrast, lymphocytes primed in 
peripheral lymph nodes express ligands for vascular P- and E-selectins and the 
chemokine receptors CCR4 and/or CCR10.  Local resident dendritic cells (DC) play 
an important role in instructing naïve lymphocytes to express the appropriate 
homing receptor profile (63, 105, 138). For example, DC isolated from Peyer’s 
patches or mesenteric lymph nodes induced α4β7 and CCR9 expression in co-
cultured T or B cells whereas DC isolated from peripheral lymph nodes promoted 
the expression of P- and E-selectin ligands. The ability of intestinal DC to 
confer gut tropism to T cells may not necessarily be the attribute of a 
distinct, tissue restricted DC subset (63,105). Rather, the local tissue 
(cytokine) environment and microbial signals play a dominant role in shaping the 
mucosal imprinting capacity of DC (31,32,68). 
In addition to their ability to promote gut-tropism of T cells mucosal DC are 
characterized by their capacity to induce IgA responses and by their 
preferential secretion of the cytokines IL-10, TGF-β and IL-6 (55).  
 
Interestingly, the ability of intestinal DC to promote lymphocyte targeting to 
the gut was linked to their unique expression of retinoid hydrogenase enzymes 
which convert dietary vitamin A to retinoic acid. Retinoic acid is a natural 
bioactive metabolite of vitamin A which regulates a broad range of biologic 
processes including inflammation, and cell differentiation and proliferation 
through binding to specific nuclear retinoid receptors present in many cell 
types including T and B cells (10). With regard to lymphocyte differentiation, 
retinoic acid was shown to directly up-regulate α4β7 and CCR9 expression on T 
cells (56). In addition to this modulation of the homing properties of T 
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lymphocytes to mucosal sites, gut DC-derived retinoic acid was also identified 
among other factors as an important inducer of IgA secretion in B cells (106).  
Recent experiments performed also in large animal models investigated the 
potential of peripheral DC to be modulated towards a mucosa-type DC. This would 
enable the induction of mucosal immune responses after parenteral administration 
of antigen and some support for the feasibility of this has been obtained (132). 
Porcine monocyte-derived DC pre-treated with the vitamin A derivative all-trans 
retinoic acid (RA) acquired several attributes characteristic of mucosal DC, 
including (i) secretion of the cytokines TGF-β and IL-6, (ii) the capacity to 
induce IgA responses and (iii) the ability to induce expression of mucosal 
homing receptors in co-cultured lymphocytes (132). Transwell experiments 
separating the cell populations in an in vitro porcine co-culture model revealed 
that RA-treated monocyte-derived DC mediate their effects through soluble 
factors rather than through cognate receptor interaction with lymphocytes. 
Although no IL-10 was detectable in supernatants from RA-treated monocyte-
derived DC, RA was found to induce TGF-β. Addition of a pan-TGF-β neutralizing 
monoclonal antibody reduced the capacity of the RA-treated monocyte-derived DC 
to induce integrin α4β7 up-regulation in co-cultured lymphocytes significantly. 
Up-regulation of CCR9 mRNA induced by RA-treated porcine monocyte-derived DC was 
not affected by the presence of the TGF-β neutralizing monoclonal antibody. 
Thus, β7 integrin and CCR9 expression in this large animal in vitro model appear 
to be differentially regulated similar to what has been described in the mouse 
system (63, 105).  
The ability to induce specific IgG and IgA responses was also investigated using 
food and mouth disease virus (FMDV) as antigen (132). It could be shown that RA 
treated monocyte-derived porcine DC are potent inducers of specific IgG and IgA 
responses. Similar experiments in the presence of a RA receptor antagonist 
revealed that α4β7 integrin and CCR9 mRNA expression was suppressed, but IgA 
production remained unchanged suggesting that a different mechanism contributes 
to these effects on T and B lymphocytes. 
  
The role of RA as a mucosal immune modulator would be consistent with the 
location of mucosal DC in the vicinity of RA-producing intestinal epithelial 
cells (85) and the autocrine production of RA by intestinal DC. Initial in vivo 
immunization experiments revealed that the application of RA in a vitamin A 
deficiency model in rats enhanced the antibody response to tetanus toxoid (28). 
The transcutaneous application of RA with cholera toxin and whole inactivated 
influenza virus augmented the intestinal anti-influenza virus response compared 
with a cholera toxin virus combination (136). Whether migration of peripheral DC 
to mucosal inductive sites or the imprinting of mucosal homing receptor 
expression in local draining lymph nodes account for these effects need to be 
investigated in future studies (13,36,132).  
These findings suggest a novel role for RA as a mucosal immune modulator 
targeting DC, which is of particular interest for adjuvant and also nutritional 
applications. 
Interferons 
Dendritic cells (DC) and particularly the interaction between conventional 
‘myeloid’ DC (cDC) and plasmacytoid DC (pDC) are important for efficient immune 
defence functions (pDC are also known as natural interferon producing cells). 
The host immune system is often manipulated by viral pathogens infecting DC. The 
manner by which different viruses interfere with DC function depends on both the 
virus and the subset of DC involved. The recognition of viral nucleic acids by 
pattern recognition receptors (PRRs) is the first step in inducing the innate 
immune system. Type I interferons, central mediators in antiviral innate 
immunity, along with other cytokines and chemokines, disrupt virus replication. 
Recent studies indicated at least two distinct pathways for type I interferon 
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induction by viral infection, one mediated by retinoic acid-inducible gene-I 
(RIG-I) and one mediated by melanoma differentiation-associated gene 5 (MDA5).  
 
In addition to their direct antiviral activity, type I interferons also posses 
major immunomodulatory abilities. In vivo experiments showed that type I 
interferons can potently enhance humoral immunity and promote isotype switching 
(89). Type I interferons secreted by pDC have been shown to induce B-lymphocytes 
to differentiate into antibody producing plasma cells and to be necessary for 
the production of both specific and polyclonal humoral immune responses after 
influenza virus infection (124). With regard to an adjuvant effect in 
vaccination experiments, type I interferons were shown to have potent activities 
when co-administered with inactivated vaccine preparations applied through the 
parenteral route (60, 149). Humoral IgG and IgA levels were significantly 
elevated in a dose-dependent manner when interferon-alpha was co-administered 
with an inactivated influenza vaccine. In contrast, intraperitoneal application 
of interferon-alpha at a distant site of the vaccination antigen rather 
decreased the humoral immune response (149). Characterization of the cell 
population activated by the interferon-alpha co-administration revealed that 
populations corresponding to cDC and pDC were involved. Therefore, trafficking 
of antigen presenting cells towards the site of vaccination may explain at least 
in part the mechanism underlying the adjuvant activity of interferon-alpha when 
co-administered with inactivated vaccine preparations (149). 
To investigate the species specificity of commercially available interferon-
alpha human (HRT-18, Panc), simian (Vero), and bovine (MDBK) cells were treated 
with commercially available human recombinant interferon-alpha expressed in 
Escherichia coli (Sigma-Aldrich®). Reactivity of the cells was tested by the 
induction of the antiviral Mx protein using the anti-Mx antibody M143 (39). As 
shown in Figure 6 (Suppl. info) the human recombinant interferon induced Mx 
protein synthesis in human, simian as well as bovine cells in a dose-dependent 
manner. Interestingly the strongest induction was observed in the cells of 
bovine origin, which should be further investigated.  
 
Well-defined carrier/delivery systems: Particulate antigen 
delivery systems for mucosal immunity. 
The delivery of purified antigens by encapsulation into particulate, non living, 
systems offers a range of advantages such as 1) enhancement of the 
immunogenicity of soluble antigens, 2) increase of the antigen uptake, 3) 
protection of the antigens, 4) reduction of the antigen dose, and 5) control of 
antigen release. Another major advantage is the capacity for mucosal antigen 
delivery. This route is the most relevant to trigger protection since almost 90% 
of all pathogens, regardless of which species, enter and initiate infection at 
mucosal surfaces (45). IgA, the main mucosal immunoglobulin, cannot be induced 
by parenteral inoculation and thus systemic (parenteral) vaccination only 
triggers incomplete protection against mucosal infections, although partial 
transfer of IgG1 and IgG2 from serum into the lung was demonstrated in cattle 
(17). However, soluble antigens are poor immunogens by oral or nasal routes and 
adjuvants or delivery systems for these kinds of antigens are needed to induce 
mucosal immune responses (25). Mucosal immunization elicits strong mucosal 
immune responses even in remote mucosal sites (the existence of a common mucosal 
immune system has been confirmed in large animals (133), and in addition a 
systemic immune response – depending on the size of the particles.  
The advantages of particulate antigen delivery systems for mucosal immunization 
include 1)protection of antigen against the gastrointestinal environment (acid 
and proteolytic enzymes), 2) enhancement of antigen translocation to the mucosa-
associated lymphoid tissue, 3) ease of delivery via the oral or intranasal 
route. A variety of particulate systems has been developed; here we will focus 
on microparticles and liposomes. 
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Microparticles: Uses in ruminants. 
Microparticles (MP) can be derived from different polymers including poly-
lactide-coglycolide (PLG)(Figure 7, Suppl. info.), alginate, and starch or other 
carbohydrate polymers. Compared to PLG MP, the manufacture of which requires the 
use of organic solvents that may alter antigenic epitopes, alginate MP are 
produced using mild conditions (45, 126) using an inexpensive, non-toxic, 
naturally occurring polysaccharide that is also biodegradable. Alginate MPs are 
compatible with a variety of antigens, have proved useful to circumvent the 
maternal antibodies in vaccination of young animals (75), and improve capture of 
DNA by antigen presenting cells (APC)(152). A direct adjuvant role for the 
alginate has also been suggested (126). Biodegradable MP were originally 
developed for oral delivery (126), however, although demonstrating high efficacy 
in small animal models, few of them were tested in large animals.  
  
For parenteral delivery, a single injection in cattle of a Staphylococcus aureus 
lysate encapsulated in biodegradable PLG microparticles (Sta-MP) was 
investigated using a 50/50 mixture of small (<10µm) and large (>10µm) particles 
emulsified in Freund’s incomplete adjuvant (FIA)(117). This resulted in an 
antibody response similar to that obtained when emulsifying the antigen in FIA, 
although with a lower level, likely due to the slow release of the antigens. The 
Sta-MP-elicited antibodies supported phagocytosis at ahigher level than 
unencapsulated antigens. It was suggested that the small MP (<10µm) were taken 
up by APC while the larger (>10µm) served as antigen depot slowly releasing the 
antigen over an extended period of time. It can therefore be envisaged that a 
long-term functional antibody response can be elicited by a single injection. 
Another study reported on the delivery of naked DNA plasmids encoding protective 
foot-and-mouth disease (FMD) antigens and ovine GM-CSF in sheep after 
formulation in PLG MP, compared to administering the plasmids only, plasmids in 
alum or in lipofectin, using intradermal and intramuscular injection (114). The 
formulation in MP proved to be the only one able to trigger an FMD-specific 
cell-mediated immune response. The level of protection against FMDV challenge 
was similar to that obtained by a conventional vaccine. In contrast, no immunity 
was induced in sheep by the nasal route, even in the presence of the E. coli 
labile toxin. These findings confirm that PLG MP can be used for DNA vaccination 
by the parenteral route. 
 
The efficacy of MP in inducing mucosal immunity was evaluated in cattle and it 
was demonstrated that after oral delivery, particles less than 5 µm were rapidly 
translocated to the lymphatics and disseminated to the systemic lymphoid organs 
while MP greater than 5 µm remained in the Peyer’s patches with a very slow 
translocation to the efferent lymphatics (75, 164). Therefore, small MP may 
induce a systemic as well as a mucosal immune response whereas larger MP may 
only induce a local response. The efficacy of alginate or PLG-MP to elicit a 
mucosal immune response against model antigens such as ovalbumin (OVA) and 
porcine serum albumin (PSA) was also studied in cattle. In one study, OVA was 
encapsulated in alginate MP with 70% of the MP having a diameter less than 10µm 
and 30% less than 50µm (17). These OVA-MP were then entrapped in larger alginate 
macrospheres (4-5 mm) and placed in gelatine boluses for oral delivery to 
cattle. This system has been shown to release the encapsulated material into the 
lower intestinal tract. Compared to control animals, cattle receiving two oral 
regimens (each including five daily doses of 5 mg OVA) with a 2-week interval, 
presented a significantly higher number of anti-OVA IgA antibody-secreting cells 
(ASC) in their bronchoalveolar lavages (BAL). This study also showed that 
priming by the subcutaneous route with OVA greatly enhanced the mucosal response 
with higher numbers of anti-OVA IgA, IgG1 and IgG2 ASC in the BAL as well as 
anti-OVA IgG1 ASC in the blood (17). This indicates that the antigen was well 
protected by alginate macrosphere encapsulation and able to trigger an IgA 
response even in the pulmonary mucosal system after oral administration. Also, 
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oral boosting with an antigen encapsulated in MP enhanced the protection 
obtained by subcutaneous vaccination with the same antigen. 
A comparison between oral and intranasal delivery in cattle of pig serum albumin 
(PSA) contained within alginate MP (126) did not lead to the same conclusions as 
in the above study as it was found that only intranasal delivery led to a PSA-
specific humoral response, but with IgG1 being the only significant 
immunoglobulin isotype in serum, saliva and nasal secretions and with no 
cellular response and no statistically significant anti-PSA IgA response. The 
lack of a clear mucosal IgA response is surprising, however 64 % of particles 
were less than 2µm and only 5% were bigger than 5µm which is different from the 
above study. It is possible that in cattle this range of sizes allows the 
particles to bypass the local lymphoid tissues and go directly to the draining 
lymph nodes. Intranasal delivery was also investigated in cattle by Kavanagh et 
al. (72) using OVA-containing PLG MP less than 2.5µm. The objective was to 
define the optimal dose of OVA and timing of the booster inoculation to elicit 
an IgA response. A significant, but moderate, mucosal IgA and serum IgG response 
was achieved with 1 ml of PLG-MP containing 1 mg of OVA administered into each 
nostril. The determination of the timing of the booster inoculation did not 
result in clear cut differences, although a boost at 3 weeks showed higher 
overall OVA-specific IgA levels. This finding might be due to sustained release 
of the antigen which may give unpredictable results. Nevertheless, this 
sustained antigen release allowed the generation of a prolonged IgA response up 
to 5 months following an intranasal boost given at week 5.  
 
These studies illustrate that mucosal immunization is more challenging than 
parenteral delivery. Critical factors include the MP size and composition as 
well as the protocol and anatomical site for the mucosal delivery. In ruminants, 
the gut-associated lymphoid tissues (GALT) is located as patches in the jejunum, 
ileum, colon and rectum with M cells identified in all sites (92). However, 
internalization of latex beads (250 and 610nm) was only demonstrated with M 
cells of the ileum and not with those of the jejunum (92). Concerning the nasal-
associated lymphoid tissues (NALT), in ruminants, it is located in the 
nasopharynx, posterior to the opening of the Eustachian tube (92). Besides the 
NALT, the lymphoid tissues of the Waldeyer’s ring are even more developed in 
farm animals. They guard the nasal (pharyngeal and tubal tonsils), oral 
(lingual, palatine and soft palatine tonsils) and auditory passage into the 
pharynx. M-like cells were identified in the pharyngeal and palatine tonsils of 
the sheep (92) and the function of the ovine NALT as a potent antigen sampling 
site has been demonstrated (139). Furthermore, in ruminants, other lymphoid 
tissues, such as the bronchus-associated lymphoid tissue (BALT), can be induced 
by antigen exposure (92). Thus all of these lymphoid tissues play a major role 
as active inductive mucosal sites. The anatomical localization of the intranasal 
immunization, depending on the particle size and delivery device, is thus also a 
critical point in triggering optimal mucosal responses. It will determine if the 
antigen-loaded MP will reach and be retained in the relevant tissues for 
sustained antigen release or be entrapped and rejected by the nasal mucus.  
To further characterize the uptake of alginate MP and their ability to trigger a 
mucosal response, in vitro experiments were performed in a sheep intestinal 
“loop” model (75,112) using PSA as the encapsulated antigen. First, a 
comparative analysis was made between MP of less than 10µm and MP over 10µm.  
The results revealed that only MP <10µm attached to the follicle-associated 
epithelium overlying the Peyer’s patches within which M cells are contained, 
confirming previous observations made in mice and pigs (75). The uptake of the 
PSA-MP was confirmed by the presence of numerous PSA-specific antibody-secreting 
cells of IgG and IgA isotypes in the Peyer’s patches (75). Induction of a 
systemic humoral response was also observed but no cellular response (112). 
Although no cell-mediated immune response was detected in these studies, there 
is evidence that MP can induce cellular immunity in mice following mucosal 
immunization with proteins and may preferentially induce a Th1 response (112).  
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These findings demonstrate that MP with a diameter less than 10µm can be an 
efficient antigen delivery system for oral immunization if they can reach the 
relevant mucosal lymphoid tissues where the cellular uptake takes place. 
Similarly, Rebelatto et al. (126) reported an old study demonstrating that in 
calves, tonsils could absorb resin particles of 1-5µm in diameter. Then, as 
described above, an optimal balance between differently sized MS should be 
defined to allow both mucosal and systemic immune responses and long term 
immunity. Appropriate delivery to the mucosal inductive sites is a critical 
requirement for vaccine efficacy.  
 
Microparticles: Uses in pigs. 
Since 1992, when Weng et al. reported on the protective effects of an oral 
microencapsulated M. hyopneumoniae vaccine against experimental infection in 
pigs (156), only a few studies had been published on the usability of 
microparticles for vaccine delivery in pigs. Some of these delivery systems 
remained unsuccessful or are largely untested for oral vaccine delivery in large 
animals (92,112). Felder et al. (37) examined the feasibility of peroral 
immunisation with microencapsulated Escherichia coli and detached fimbriae to 
prevent enterotoxigenic E. coli infections in pigs. Various MP formulations 
designed to deliver priming and booster doses were fed to new-born and weaned 
pigs. No significant serum IgA antibodies were induced and after peroral 
homologous challenge 19 days after the booster vaccination E. coli colonisation 
was not reduced. 
The apparent discrepancy between results from small and large animals suggests 
that additional barriers may impede the local trafficking of MP throughout the 
GALT. Torche et al. (148) investigated the systemic immune response after 
administration to pigs of a model antigen (IgY), either in solution or 
encapsulated in PLG MP. A surgical experimental model ensured local delivery of 
IgY at different GALT locations including the intestinal lumen, in mesenteric 
lymph nodes and within Peyer’s patches. It was found that PLG MP were able to 
elicit a combined serum IgG2/G1 response with a predominance of IgG1 when 
locally administered. PLG MP could be a potential oral delivery system for 
antigen, however these results further underline the difficulty associated with 
immunizing large animals like pigs.  
During the last ten years, work has been performed on the targeting of MP to 
antigen presenting cells to improve their potency. Thus modified PLGA MP with 
specific ligands on their surface for increasing their cellular uptake have been 
investigated in vitro on pig alveolar macrophages (145,147). An ex vivo assay 
was also performed on a pig ileal Peyer's patch segment to confirm the traffic 
of PLG MP throughout M cells (146). Brandhonneur et al. (18) studied cationic 
(poly-L-lysine grafted) PLG MP and ligands such as wheat germ agglutinin, 
mannose-PEG3-NH2 and arginine-glycine-aspartic acid grafted on PLG MP in this 
system and found their uptake by macrophages to be increased. However, the 
relative contribution of specific and non-specific uptake varied according to 
the ligands, and was dependent on the particle-to-cell ratio. Jiang et al. (62) 
describe the potential of mannosylated chitosan microparticles to target mouse 
macrophage mannose receptors. Non grafted chitosan microparticles were 
previously shown to be effective in pigs in inducing specific immune responses 
against Bordetella bronchiseptica (67). 
 
Liposomes: Uses in ruminants. 
Due to their flexibility with regard to size, composition, charge and bilayer 
fluidity as well as their ability to incorporate large amounts of antigens and a 
variety of hydrophilic or hydrophobic compounds, liposomes are interesting 
antigen delivery systems. In vaccine applications, their main functions are to 
protect the antigens from clearance in the body and to deliver the antigens to 
professional antigen-presenting cells (Figure 1). They are classically composed 
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of natural, biodegradable, nontoxic and nonimmunogenic phospholipids in which 
antigen is either enclosed within the core, corresponding to an aqueous phase, 
or intercalated into the lipid layer (9, 54). Liposomes might be used as 
carriers for proteins, peptide-derived antigens and for nucleic acids encoding 
antigens (DNA plasmids, mRNA) or targeting genes (siRNA) (9, 51, 64).  
Liposomes may have natural adjuvant properties depending of their lipid 
composition. For example, an increase of IFN-γ secretion by murine spleen cells 
was observed ex vivo when phosphatidylserine is used as neutral lipid in 
liposome formulation (6). Liposomes can also influence antigen presentation. It 
has been described that an antigenic protein delivered by conventional liposomes 
was processed via the class II molecules of the major histocompatibility complex 
(MHC II) pathway, while MHC I presentation could be achieved with pH-sensitive 
liposome carriers (91). Also, liposomes can be made directly immunostimulatory 
by including microbial PAMPs. For example, antigen presenting cell activation 
through interaction with TLR or CD14 was reported when lipopolysaccharide (LPS) 
derivatives were added in liposome formulation (54). By optimizing the lipid 
composition and biophysical properties of liposomes, it is also possible to 
target specific tissues or cell-types. Several groups report that cationic 
liposome-encapsulated antigens are phagocytosed by dendritic cells to a much 
greater extent than anionic particles, inducing their activation and leading to 
increased efficiency of presentation to the immune system (40, 130,143)(Figure 
8, Suppl. info.). The mechanism behind these differences in passive targeting of 
antigen presentation remains unknown. Active cell-targeting can be achieved by 
the use of engineered lipids. As an example, it has been observed that addition 
of mannosylated phosphatidylethanolamine, specifically recognised by mannose 
receptors, leads to specific delivery to CD11c+ antigen presenting spleen cells 
after systemic injection (52). To target other cell-types, liposomes coated with 
immunoglobulin or Fab fragments have been developed. In this case, specific 
cell-attachment of “immunoliposomes” is a function of the affinity and avidity 
of the Ig towards a cell-surface marker (99). In addition, liposomes have been 
used widely for oral and intranasal delivery of antigens in mice. For this 
purpose, improved delivery was achieved by conjugation of the liposomes with 
recombinant B subunit of cholera toxin or IgA (45,164). 
Very few liposome formulations have been used in veterinary medicine; this 
includes uses as a novel antitumor drug delivery system or vaccine for dogs and 
cats (98, 122,150). Tana et al. showed that cationic liposomes were efficient in 
promoting diphtheria toxin A-chain gene delivery in bovine leukemia virus 
infected cells after intratumoral injection (142). Subunit vaccines based on 
liposome-encapsulated antigenic protein have also been assessed. Subcutaneous 
immunisation against bovine herpesvirus type 1 with liposome-entrapped 
herpesvirus antigen and IL-12 has been reported to elicit induction of antigen-
specific cellular and humoral immune responses (9). More recently, liposomal 
delivery of recombinant antigen has been described to enhance the immune 
response against Brucella abortus in mice (97). Assessment of intramuscular 
delivery in cattle of a liposome-based DNA vaccine against bovine viral 
diarrhoea virus was described by Harpin et al. (51). These authors reported that 
lipoplexes, formed by plasmid encoding the major glycoprotein E2 and 
conventional cationic liposomes were able to enhance the immune response 
compared to naked DNA.  
A new generation of engineered liposomes holds promise for even more efficient 
immunostimulation. For example, immunization of cattle with recombinant major 
piroplasm surface protein from Theileria sergenti encapsulated by mannan-coated 
liposomes has been reported to be an efficient inducer of T-cell immune 
responses (64). 
 
Conclusions and perspectives 
There is considerable interest in mucosal routes of vaccination in livestock 
since they obviate the problems associated with injection, stress and handling 
of the animals and do not require trained personnel and as a large number of 
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infections are of mucosal origin. Both microparticles and liposomes have proved 
efficient for mucosal vaccine delivery in small animal models (45). Their study 
in large animals is still at an early stage; however the results achieved 
warrant further experiments. Microparticulate delivery represents an efficient 
and cost effective vaccine strategy with particular relevance for developing 
countries. Oral delivery, the most attractive route for mucosal immunization of 
livestock, might be used to achieve mucosal immunity not only in the digestive 
tract, but also in the lungs. Even so, nasal vaccination may provide a practical 
alternative to the oral immunization because of its relative accessibility, high 
permeability of the local lymphoid tissues, less acidic pH and lower levels of 
enzymatic activity compared to the gut lymphoid tissues (139). This may be of 
particular importance in ruminants since orally administered antigens have to 
pass through the rumen before reaching the target GALT. 
 
The studies reported above offer preliminary proof of concept that encapsulating 
antigens in particulate system protects the antigen, facilitates and controls 
its uptake either by antigen presenting cells or by the M cells of the nasal or 
intestinal mucosae and triggers an immune response. Further enhancement of 
mucosal immune responses may be obtained by optimizing the antigen dose, the 
size and composition of the particles, improving cell targeting, and by 
incorporating relevant adjuvants/immunomodulators. Particulate delivery systems 
can accomodate both antigens, immunomodulators and targeting molecules at the 
same time and the simultaneous presence of antigen, adjuvant and a targeted 




The development of novel safe, efficient and yet cost effective vaccine 
formulations is a great challenge, although a large panel of innovative 
strategies are being investigated and significant advances have been achieved. 
The majority of these studies are conducted in small animal (rodent) models and 
the translation of results from small to large animals is not a trivial task. 
Apart from a whole range of differences in the finer details of the molecular 
mechanisms and the physiology of the immune system between species there are 
also major differences related to general physiology that invites substantially 
different vaccine strategies and methods to be used, especially when considering 
mucosal immunization. There are also interesting differences in reaction 
patterns towards different types of PAMs, including CpG-containing DNA, possibly 
evolutionarily adapted to the spectrum of infections that commonly occur in a 
given species. Other variations in PAMP responsiveness are seen, for example 
there are major differences in responsiveness to lipopolysaccharides between 
species. On top of this there are a number of practical considerations related 
to production/rearing practices, economical concerns and animal “use” 
considerations (meat quality, fur blemishes etc.) that are not relevant for 
humans and for laboratory rodents. 
Therefore, the potential of new vaccine formulation strategies for improving 
veterinary vaccines still remains largely unexploited, although there is a great 
need for needle free, cost effective, single shot vaccines triggering long 
lasting immunity in large animals, including livestock. 
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Figure and Table legends 
 
Figure 1: 
Schematic showing the possibility of incorporating various components with 
potential for vaccine delivery and efficacy into liposomes. 
 
Table 1:  
Summary of Toll-like receptor biology (agonists and cellular location) 
 
Table 2:  
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Supplementary information: 
 
Figure 1, suppl. info.: 
A: Physiology of the immune system showing the presence and distinct locations 
of pathogen/antigen encounter and display (DCs at infection site), antigen 
presentation and T- and B-cell stimulation (activated DCs, lymph nodes) and 
return to site of pathogen localization of high numbers of highly specific T- 
and B-cells. Figure reproduced by kind permission from Bioconj. Chem. (Heegaard 
PMH, Boas U, Sorensen NS (2010) Dendrimers for Vaccine and Immunostimulatory 
Uses.  A Review.  Bioconjugate Chem  21: 405–418) 
 
B: The innate and adaptive immunity domains depicting innate immunity as the 
provider of stimuli for the adaptive immunity to develop in specific ways 
(represented by Th1 and Th2 cells, respectively) with specific types of 
activity. Figure reproduced by kind permission from Bioconj. Chem. (Heegaard 
PMH, Boas U, Sorensen NS (2010) Dendrimers for Vaccine and Immunostimulatory 
Uses.  A Review.  Bioconjugate Chem  21: 405–418) 
 
 
Figure 2, Supplementary information:  
Subcutis, dog. Foreign lipid material eliciting piogranulomatous inflammatory 
reaction, mainly composed of macrophages, epithelioid cells and neutrophils.  
 
Figure 3, Supplementary information:  
Subcutis, cat. Post-vaccinal fibrosarcoma, characterised by highly pleomorphic 
fibroblasts, with high mitotic rate (arrowhead) intermingled with multinucleated 
giant cells (arrows), showing phagocytic activity.  
 
Figure 4, Supplementary information:  
Alignment of human (NM_003265) and bovine (NM_001008664) TLR3 sequences (a) and 
phylogenetic tree showing evolutionary relationship between avian and mammalian 
TLR3 (b). 
 
Figure 5, Supplementary information:  
CpG ODN D19 (65) effects on pig PBMCs. The production of selected cytokines 
after overnight culture with either D19 (black boxes) or its variant in which 
the only change is that CpG is inverted to GpC (white boxes). For clarity all 
cytokines are depicted in the same figure. As detection limits vary they are 
depicted for each cytokine (dotted lines). Controls (cells cultured in the 
presence of medium only) always produced cytokines below the detection limit. 
Means and SEMs are shown for PBMCs from 6 animals. 
 
Figure 6, Supplementary information:  
HRT-18 (A), Panc (B), Vero (C), and MDBK (D) cells were incubated for 12h in the 
presence of the indicated amounts of human recombinant interferon-alpha 
(concentrations between 100000 and 10 Units). Cells were dissolved in Laemmli 
buffer, separated on 10% SDS-polyacrylamide gels, transferred to nitrocellulose 
membranes and subsequently stained with monoclonal antibody M143 kindly proved 
by G. Kochs (University of Freiburg, Germany). The secondary antibodies were 
goat anti-mouse IgG coupled to HRP. 
 
Figure 7, Supplementary information:  
(a) Scanning electron micrograph showing PLG-OVA microspheres (bar represents 
5µm). (b) Single microsphere after 4 weeks in PBS, showing large fissure in 
polymer surface (bar represents 1µm) (reproduced by permission from Kavanagh et 
al. (72), License number: 2085771131023) 
 
Figure 8, Supplementary information:  
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Interaction between liposomes and murine dendritic cells: Confocal microscopy 
analysis of the interaction between murine bone marrow-derived dendritic cells 
and various liposome (bright) formulations. A and C: Anionic liposomes;  B : 
Mannosylated liposomes; D : Cationic liposomes.  Bars: 10 µm. (reproduced by 
permission from Foged et al. (41), License number: 2112511301139) 
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